Abstract
The transition from laboratory testing to evaluation in humans marks an important stage in vaccine development. Questions about safety and benefit to the patient and to the community may raise difficult ethical issues, whereas the inherent variability of human responses must be taken into account to obtain valid estimates of vaccine effect. This latter requirement explains why a coherent statistical framework for the design, analysis, and interpretation of clinical trials is regarded as essential today. A vast body of experience and methodology has been developed since the 1940s, when the scientific method was first applied systematically to the evaluation of vaccines. A striking feature of clinical trial research is its broad collaborative nature, involving laboratory, epidemiological, clinical, and statistical skills. As a consequence, rather than attempt to describe in detail the planning and conduct of clinical trials, this chapter will review the broad principles and stages involved in evaluating vaccines in humans, using examples from the literature. Details of methodological and other issues of particular relevance to vaccine evaluation are provided in Section 3.
Similar content being viewed by others
References
Byar, D. P., Schoenfeld, D. A., Green, S. B., Amato, D. A., Davis, R., DeGruttda, V., et al. (1990) Design considerations for AIDS trials. N Engl. J. Med. 323, 1343ā1348.
Bellanti, J. A., Zeligs, B. J., Vetro, S., Pung, Y.-H., Luccioli, S., Malvasic, M. J., Hook, A. M, Ubertini, T. R., Vanni, R., and Nencioni, L. (1993) Studies of safety, infectivity and immunogenicity of a new temperature-sensitive (ts) 51-1 strain of Salmonella typhi as a new live oral typhoid fever vaccine candidate. Vaccine 11, 587ā590.
Costantino, P., Viti, S., Audino, P., Velmonte, M. A., Nencioni, L, and Rappuoli, R. (1992) Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 10, 691ā698.
Gold, R., Leplow, M. L., Goldchneider, I., Draper, T. F., and Gotschlich, E (1979) Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children J. Infect. Dis. 140, 690ā697.
Rutter, D. A., Ashworth, L. A. E., Day, A., Funnell, S., Lovell, F., and Robinson, A. (1988) Trial of a new acellular pertussis vaccine in healthy adult volunteers Vaccine 6, 29ā32.
Bock, H L, Klockmann, U., Jungst, C., Schindel-Kunzel, F., Theobald, K., and Zerban, R. (1990) A new vaccine against tick-borne encephalitis: initial trial in man including a dose-response study. Vaccine 8, 22ā24
Picard, O, Giral, P., Defer, M. C., Fouchard, M., Morel, M, Meyohas, M. C, et al. (1990) AIDS vaccine therapy: phase I trial (letter). Lancet 336, 179.
Scheifele, D., Bjornson, G., Barreto, L, Meekison, W., and Guasparini, R. (1992) Controlled trial of Haemophilus influenzae type B diphtheria toxoid conjugate combined with diphtheria, tetanus and pertussis vaccines, in 18-month old children, including comparison of arm versus thigh injection. Vaccine 10, 455ā460.
Miller, E, Ashworth, L A., Robinson, A., Waight, P. A, and Irons, L. I. (1991) Phase II trial of whole-cell pertussis vaccine versus an acellular vaccine. Lancet 337, 70ā73.
Pichichero, M. E., Marsocci, S. M., Francis, A B., Green, J. L., Disney, F A., Rennels, M. B., Lewis, E. D, Sugarman, L., Losonsky, G. A., Zito, E., and Davidson, B. L. (1993) A comparative evaluation of the safety and immunogenicity of a single dose of unbuffered oral rhesus rotavirus serotype 3, rhesus/human reassortant serotypes 1, 2 and 4 and combined (tetravalent) vaccines in healthy infants Vaccine 11, 747ā753.
Strauss, S. E., Corey, L., Burke, R. L., Savarese, B., Barnum, G., Krause, P. R., Kost, R. G., Meir, J. L., Sekulovich, R., Adair, S. F., and Dekker, C. L. (1994) Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343, 1460ā1463.
Valero, M. V., Amador, L. R., Galindo, C., Figueroa, J., Bello, M. S., Murillo, L. A, et al (1993) Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum malaria in Colombia. Lancet 341, 705ā710.
Sempertegui, F., Estrella B, Moscoso, J, Piedrahita, L, Hernandez, D., Gaybor, J., et al. (1994) Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12, 337ā342.
Hall, A. J. and Aaby, P. (1990) Tropical trials and tribulations. Int. J. Epidemiol. 19, 777ā781.
Francis, T, Korns, R. F., Voight, T., Boisen, M., Hemphill, F. M., Napier, J. A., and Tolchinsky, E. (1955) An evaluation of the 1954 poliomyelitis vaccine trials. Am J Public Health Part 2 45, 1ā63.
Fine, P. E M. and Clarkson, J. A. (1987) Reflections on the efficacy of pertussis vaccines. Rev. Infect. Dis. 9, 866ā883.
Vesikari, T. (1993) Clinical trials of live oral rotavirus vaccines: the Finnish experience. Vaccine 11, 255ā261.
Medical Research Council (1951) The prevention of whooping-cough by vaccination: a Medical Research Council investigation. Br. Med. J. June 30, 1463ā1471.
Farrington, C. P. (1990) Quantifying misclassification bias in cohort studies of vaccine efficacy. Stat Med. 9, 1327ā1337.
PHLS Epidemiological Research Laboratory and 21 Area Health Authorities (1982) Efficacy of pertussis vaccination in England. Br. Med. J. 285, 357ā359.
Storsaeter, J., Hallander, H., Farrington, C. P., Olin, P., Mollby, R, and Miller, E. (1990) Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 8, 457ā461.
Ad-Hoc Group for the Study of Pertussis Vaccines (1988) Placebo-controlled trial of two acellular pertussis vaccines in Sweden: protective efficacy and adverse events. Lancet April 30, 955ā960.
Volberding, P. A, Lagakos, S. W., Koch, M A., Pettinelli, C., Myers, M W., Booth, D. K., et al. (1990) Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N. Engl J. Med. 322, 941ā949.
Simanjuntak, C. H., Paleologo, F., Punjabi, N. H., Darmowigoto, R., Soeprawoto, Totosuderjo, H., Haryanto, P., Suprijanto, E., Witham, N. D., and Hoffman, S. L. (1991) Oral immunisation against typhoid fever in Indonesia with Ty2la vaccine Lancet 338, 1055ā1059.
Storsaeter, J., Olin, P., Renemar, B., Lagergard, T, Norberg, R., Romanus, V, Tiru, M., et al. (1988) Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect. Dis. J. 7, 637ā645
Garenne, M., Leroy, O., Beau, J.-P., and Sene, I. (1991) Child mortality after high-titre measles vaccines: prospective study in Senegal. Lancet 338, 903ā907.
Medical Research Council Whooping Cough Immunisation Committee (1956) Vaccination against whooping cough: relation between protection and results of laboratory tests Br. Med J. 2, 454ā462.
Orenstein, W. A., Bernier, R. H., Dondero, T. J., Hinman, A. R., Marks, J. S., Bart, K. J., and Sirotkin, B. (1985) Field evaluation of vaccine efficacy. WHO Bulletin 63, 1055ā1068.
Begg, N. and Miller, E. (1990) Role of epidemiology in vaccine policy. Vaccine 8, 180ā189.
PHLS Whooping-Cough Committee and Working Party (1973) Efficacy of whooping-cough vaccines used in the United Kingdom before 1968. Br. Med. J. Feb. 3, 259ā262.
Miller, E., Goldacre, M., Pugh, S., Colville, A., Farrington, P., Flower, A., Nash, J., MacFarlane, L., and Tettmar, R. (1993) Risk of aseptic meningitis after measles mumps and rubella vaccine in UK children. Lancet 341, 979ā982.
Farrington, P., Pugh, S., Colville, A., Flower, A., Nash, J., Morgan-Capner, P., et al. (1995) A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345, 567ā569.
Diamond, A L and Laurence, D. R (1983) Compensation and drug trials (Commentary) Br Med. J. 287, 676ā677.
Association of the British Pharmaceutical Industry (1983) Compensation and drug trials. Br. Med. J. 287, 675.
Pocock, S.J. (1983) Clinical Trials A Practical Approach. Wiley, Chichester.
Farrington, C. P. and Manning, G. (1990) Test statistics and sample size formulae for comparative binomial trials with null hypotheses of non-zero risk difference or non-unity relative risk. Stat. Med. 9, 1447ā1454.
Machin, D. and Campbell, M. J. (1987) Statistical Tables for the Design of Clinical Trials Blackwell Scientific, Oxford.
Altman, D. G. and Dore, C. J. (1990) Randomisation and baselie comparisons in clinical trials. Lancet 335, 149ā153.
Levine, M. M., Fereccio, C., Cryz, S., and Ortiz, E. (1990) Comparison of entericcoated capsules and liquid formulation of Ty2la typhoid vaccine in randomised controlled field trial. Lancet 336, 891ā894.
Newell, D. J. (1992) Intention-to-treat analysis: implications for quantitative and qualitative research. Int. J. Epidemiol. 21, 837ā841.
Farrington, C. P. (1993) Intention-to-treat analysis: implications for quantitative and qualitative research (letter). Int. J. Epidemiol. 22, 566.
Medical Research Council (1966) Vaccination against measles: a clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Br. Med. J. February 19, 441ā446.
Clemens, J. D., Sack, D. A., Harris, J. R., Chakraborty, J., Khan, M. R., Stanton, B. F., Kay, B. A., Khan, M. U., Yunus, M., Atkinson, W., Svennerholm, A. M., and Holgren, J. (1986) Field trials of oral cholera vaccines in Bangladesh. Lancet July 19, 124ā127.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
Ā© 1996 Humana Press Inc, Totowa, NJ
About this protocol
Cite this protocol
Farrington, P., Miller, E. (1996). Clinical Trials. In: Robinson, A., Farrar, G.H., Wiblin, C.N. (eds) Vaccine Protocols. Methods in Molecular Medicineā¢, vol 4. Humana Press. https://doi.org/10.1385/0-89603-334-1:251
Download citation
DOI: https://doi.org/10.1385/0-89603-334-1:251
Publisher Name: Humana Press
Print ISBN: 978-0-89603-334-4
Online ISBN: 978-1-59259-588-4
eBook Packages: Springer Protocols